Show
Sort by
-
- Miscellaneous
- open access
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps : association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
-
- Miscellaneous
- open access
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
-
Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI≥ 30 kg/m2 or weight≥ 90 kg : post-hoc analysis of the SINUS-24 and SINUS-52 studies
(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB143-AB143 -
Dupilumab achieves durable reduction in severity of symptoms rated most important by patients with chronic rhinosinusitis with nasal polyps
(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB142-AB142 -
- Journal Article
- A1
- open access
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
-
Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps
(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB144-AB144 -
- Journal Article
- A1
- open access
AROMA : real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
Respiratory infections and anti-infective medication use from phase 3 dupilumab respiratory studies
-
Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies
-
- Journal Article
- A1
- open access
Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases